Ceritinib for the Treatment of Late-Stage (Metastatic) Non-Small Cell Lung Cancer

E. Massarelli, V. Papadimitrakopoulou
2015 Clinical Cancer Research  
Over the last decade the non-small cell lung cancer therapeutics landscape has been dominated by the increasing focus on identification and validation of molecular targets as well as identification of the best candidate agents to address these targets. Among the notable successes has been the approval of erlotinib, gefitinib and afatinib for the EGF receptor (EGFR) mutation and more recently crizotinib for anaplastic lymphoma kinase (ALK) gene rearrangement. Despite the excellent efficacy of
more » ... lent efficacy of crizotinib several mechanisms of resistance including secondary mutation in the ALK gene eventually result in disease progression and several second-generation ALK inhibitors, notably ceritinib has demonstrated evidence of clinical activity in this setting. This review discusses the data associated with the recent accelerated approval of ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic lung adenocarcinoma with disease progression on or who are intolerant to crizotinib.
doi:10.1158/1078-0432.ccr-14-1291 pmid:25564153 fatcat:mmdmpxen6jc6laoat4v4sys6vu